• Vaccine Name: Influenza virus NP protein vaccine (Influenza A virus (A/nt/60/1968(H3N2)))
• Target Pathogen: Influenza virus
• Target Disease: Influenza (flu)
• Vaccine Ontology ID: VO_0011531
• Type: Subunit vaccine
• Status: Research
• Antigen: Influenza A virus (A/nt/60/1968(H3N2)) NP nucleocapsid protein
• NP from Influenza A virus (A/nt/60/1968(H3N2)) gene engineering:
  • Type: Recombinant protein preparation
  • Description: Recombinant-derived nucleoprotein (rNP) from S. typhimurium expressing the cloned NP gene from A/NT/60/68 (Tite et al., 1990)
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001241
• Immunization Route: Intraperitoneal injection (i.p.)

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Mice were immunized with alhydrogel-precipitated antigen intraperitoneally or subcutaneously in the base of the tail, as indicated in the text. Alhydrogel was obtained from Wellcome Biotech (Tite et al., 1990).
• Challenge Protocol: Mice were challenged with A/R8 virus of B/Lee/40 either by aerosol inhalation in a chamber or by intranasal application of solution applied to the nose-pad of mice anaesthetized with ether. In the case oflethal challenge, deaths were recorded over a 21-day period (Tite et al., 1990).
• Efficacy: Mice immunized with Recombinant-derived nucleoprotein (rNP) from S. typhimurium expressing the cloned NP gene from A/NT/60/68 (Jones & Brownlee, 1985) were protected against a lethal challenge with Influenza A/Puerto Rico/8/34 (A/PR8) virus but showed considerable morbidity before recovery (Tite et al., 1990).